JAKi ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05305066 (ClinicalTrials.gov) | February 1, 2023 | 26/2/2022 | Stand UP to Rheumatoid Arthritis (SUPRA) | Innovative Trial Designs, Multi-omics and Advanced Computational Prediction to Transform Clinical Care in RA | Rheumatoid Arthritis | Drug: TNFi;Drug: Anti-IL6;Drug: JAKi | Marie Hudson, MD | McGill University Health Centre/Research Institute of the McGill University Health Centre;Montreal General Hospital;Lady Davis Institute | Recruiting | 18 Years | N/A | All | 75 | N/A | Canada |